Search This Blog

Monday, April 13, 2026

Travere's FILSPARI wins FDA full approval as first and only treatment for FSGS

Travere's FILSPARI wins FDA full approval as first and only treatment for FSGS, expanding label beyond IgA nephropathy

  • Approval specifically targets reduction of proteinuria in FSGS patients without nephrotic syndrome.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)